Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Surfactante pulmonar como agente para el tratamiento de heridas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160822002
Publicado:
06/09/2016
Caducidad:
06/09/2017
Resumen:
Una universidad alemana ha desarrollado una nueva estrategia de cicatrización de heridas mediante el uso de surfactante pulmonar. La investigación ha demostrado la influencia del surfactante pulmonar en los queratinocitos y el beneficio de estas interacciones para la migración celular y reparación de la herida. Este nuevo enfoque permitirá reducir considerablemente los costes en el sistema de salud. La universidad busca socios interesados en licenciar o comprar la tecnología, así como investigadores para demostrar su eficacia en ensayos clínicos.

Details

Tittle:
Lung surfactant as an agent for wound treatment
Summary:
A German university has developed a new wound healing strategy by using lung surfactant. Research has shown the influence of lung surfactant on keratinocytes and the benefit of these interactions for cell migration and wound resurfacing. This new approach will significantly reduce costs for the health care system. Partners interested in licensing or purchasing the technology are sought. Besides, the university is looking for research partners to demonstrate the effective use in clinical trials.
Description:
The treatment of non-healing chronic wounds is a challenge for the medical health care system. Chronic wounds usually develop as a result of diabetes, arterial insufficiency or venous diseases.

The main goal for wound repair is the restoration of an intact barrier against physical, chemical and microbial damage. In addition, the occurrence of excessive wound healing with scarring and contracture formation is another area where new approaches are needed. The chronic nature of wound contractures often culminates in high recurrence, multiple operations, intensive physiotherapy and extended postoperative care.

The researchers of the German university have thus developed a new wound healing strategy. The team of the Centre for Biomolecular Interactions has shown the influence of lung surfactant on keratinocytes and the benefit of these interactions for cell migration and wound resurfacing. Lung surfactants contain phospholipids and surfactant proteins and are used as standard therapy for respiratory distress syndrome in preterm infants. The positive effect of lung surfactant on wound healing was shown in vitro and in vivo. Topical application of lung surfactant or its components have an anti-inflammatory, pro-migratory and anti-fibrotic effect on skin wound healing.

By treatment of wounds with lung surfactant wound healing may be accelerated, wound closure enhanced and scar formation reduced. The proposed new therapy has the potential to significantly reduce costs for the health care system due to acceleration of wound healing and reduction of scarring. Another advantage of this approach is that lung surfactant is already approved as a drug. Therefore, marketing authorization for medical products should be gained easily.

Currently the scientists are working on the clinical tests phase 1 with probants. Therefore, the university is now looking for companies interested in research cooperation agreements. Furthermore, they are looking for partners interested in license agreements as well as commercial agreements with technical assistance.
Advantages and Innovations:
- Innovative and novel strategy for skin wound healing
- Prevention of cutaneous scarring
- Promotion of cutaneous wound repair
- Anti-inflammatory effects
- Anti-microbial effects are also expected
- Reduced costs for health care system due to acceleration of wound healing and reduction of scarring
- Lung surfactant is already approved as a drug therefore marketing authorization for medical products should be gained easily
Stage of Development:
Field tested/evaluated
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
Ideal partners would be pharmaceutical companies.
The tasks to be performed by the partner would be the organisation and implementation of clinical studies of Phase II.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas